Outlook Pharma - OTLK Net earnings per one share for the last twelve months

Official company branding of Outlook Therapeutics Corp (OTLK)

Outlook Therapeutics is creating an innovative environment for vision preservation by implementing a new standard of therapy for macular degeneration. The company relies on sustainable "green chemistry" and strict bioethics, while the stable operation of sterile filling lines ensures uninterrupted supplies. The share price history on GURU.Markets confirms these successes, with an EPS of 86.00, underscoring the fundamental resilience of the business.

OTLK Outlook Pharma: Earnings per share for the last twelve months in the range 02/11/2024 - 11/18/2026

Financial and market metric breakdowns for Outlook Pharma (OTLK)

Initial company analysis:Outlook Therapeutics Inc - OTLK
Mass-produced product of Outlook Therapeutics Inc

This indicator calculates the percentage change in net earnings per share over the last twelve months relative to the same period last year, measuring the scaling rate of real income. The trend in the annual EPS TTM growth rate allows for an assessment of the commercialization efficiency of certified bevacizumab and the speed of competitor displacement for Outlook Therapeutics (OTLK), confirming the fundamental resilience of the business by stabilizing metrics in the upper range.

Competitor analysis

Net earnings per one share for the last twelve months Alcon Inc|BLCO: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Glaukos Medical (GKOS)|Earnings per share for the last twelve months apellis.com|Belite Bio (BLTE) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Ocular Pharma (OCUL)|HROW (Harrow) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) VRDN (Viridian Corp)|LENZ Corp (LENZ) - Net earnings per one share for the last twelve months|OCS: Net earnings per share for the last 12 months|Net earnings per one share for the last twelve months eyepointpharma.com|KOD: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Aldeyra Therapeutics (ALDX)|Net earnings per share for the last 12 months KALA|IRD - Net earnings per share for the trailing year|Earnings per share for the last twelve months okyopharma.com (OKYO)|Net earnings per share (EPS TTM) Adverum Biotechnologies Inc. (ADVM)|Net earnings per share (EPS TTM) CLSD (Clearside Biomedical Inc)|Earnings per share for the trailing year NBY|Kiora Pharmaceuticals, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ALIM (Alimera Sciences, Inc.)|EYEN (Eyenovia Corp) - Net earnings per share for the last 12 months|Guardion Health Science - Earnings per share for the trailing year|Earnings per share for the last twelve months Ocuphire Pharma, Inc.|Opthea Ltd. (OPT) - Net earnings per share for the last four quarters